Neuronetics

Neuronetics, Inc. (NASDAQ: STIM) is a commercial-stage medical technology company operating in the neurohealth sector. Founded in 2003 by Bruce J. Shook, Mark Demitrack, and Noah Hutton, the Malvern, Pennsylvania-based firm is focused on developing non-invasive therapies for psychiatric disorders. The company's core offering is the NeuroStar Advanced Therapy system, a transcranial magnetic stimulation (TMS) device designed to treat patients who have not found success with traditional antidepressant medications.

The company's history is marked by significant regulatory and financial milestones. After its founding and initial seed funding in 2003, Neuronetics received its first key FDA 510(k) clearance in 2008 for the NeuroStar system to treat adults with Major Depressive Disorder (MDD). This was a pivotal moment, establishing it as a pioneer in the TMS space. The company went public in June 2018, trading on the NASDAQ under the ticker 'STIM' to raise capital for commercialization and R&D efforts. Over the years, Neuronetics has expanded its device's applications, gaining FDA clearance for Obsessive-Compulsive Disorder (OCD) and, more recently, becoming the first to receive clearance for treating MDD in adolescents aged 15-21.

Neuronetics' business model centers on the sale and lease of its NeuroStar Advanced Therapy equipment to its primary clients: psychiatrists, mental health clinics, and hospitals. A significant portion of its revenue is recurring, generated from the sale of single-use treatment session components required for each TMS procedure. Following a strategic acquisition of Greenbrook TMS, the company has also vertically integrated, now operating its own network of treatment centers, which generates clinic revenue directly. This dual approach allows Neuronetics to capture value from both equipment sales to third-party providers and the direct administration of treatments.

The NeuroStar system delivers precisely targeted magnetic pulses to stimulate areas of the brain associated with mood regulation, promoting neuroplasticity. The treatment is non-invasive, requires no anesthesia, and is administered in an outpatient setting, with sessions lasting from as little as three minutes to over thirty, depending on the protocol. To support its client clinics, Neuronetics offers programs like the Better Me Provider (BMP) network, which provides resources that have demonstrated an ability to increase patient volume. The company has continually refined its technology, introducing enhancements like the TouchStar protocol for shorter treatment times and accessories to improve coil placement.

Keywords: Neuronetics, NeuroStar, Transcranial Magnetic Stimulation, TMS therapy, Major Depressive Disorder, mental health technology, neurostimulation, non-invasive brain stimulation, psychiatric disorders, treatment-resistant depression, NASDAQ: STIM, medical device, FDA cleared, neurohealth, outpatient mental health, Bruce J. Shook, adolescent depression, obsessive-compulsive disorder, Greenbrook TMS, neuromodulation